Does Blue Cross Blue Shield of Alabama Cover Farxiga?

How BCBS Alabama Classifies Farxiga on Its Formulary

Blue Cross Blue Shield of Alabama maintains a multi-tier formulary that categorizes prescription drugs by cost and clinical preference. Farxiga appears on most BCBS AL commercial and Medicare Advantage drug lists, though its exact tier varies by plan year and benefit design.

On the majority of BCBS AL commercial PPO and HMO plans, Farxiga sits on Tier 2 (preferred brand) or Tier 3 (non-preferred brand). The distinction matters. A Tier 2 placement typically means a fixed copay between $35 and $60 per 30-day supply, while Tier 3 often triggers coinsurance of 25% to 40% after deductible. BCBS AL publishes its formulary search tool online, and members can verify their specific tier by entering "dapagliflozin" or "Farxiga" on the Blue Cross Blue Shield of Alabama member portal.

For Medicare Advantage plans administered by BCBS AL, Farxiga coverage follows Centers for Medicare & Medicaid Services (CMS) guidelines. The Inflation Reduction Act of 2022 capped annual out-of-pocket Part D spending at $2,000 starting in 2025, which reduces total exposure for Medicare beneficiaries taking high-cost brand medications 1. SGLT2 inhibitors like Farxiga are classified as anti-diabetic agents under Medicare Part D, making them eligible for standard prescription drug benefit coverage.

BCBS AL updates its formulary at least annually. Mid-year changes can occur. Always confirm coverage before filling a new prescription.

Prior Authorization Requirements for Farxiga

Most BCBS AL plans require prior authorization (PA) before covering Farxiga. This is standard practice for brand-name SGLT2 inhibitors across major insurers in Alabama and nationally.

The PA process typically requires your prescribing physician to submit documentation showing that you have a confirmed diagnosis of type 2 diabetes, heart failure (NYHA Class II-IV), or chronic kidney disease with eGFR between 25 and 75 mL/min/1.73 m². BCBS AL may also require evidence that you have tried or cannot tolerate metformin, which remains the first-line pharmacotherapy for type 2 diabetes per the American Diabetes Association (ADA) Standards of Care 2.

The typical PA decision timeline at BCBS AL runs 48 to 72 hours for standard requests. Urgent requests tied to hospital discharge or acute clinical need can receive a decision within 24 hours. If PA is denied, BCBS AL must provide a written explanation citing the specific clinical criteria that were not met.

Step therapy requirements apply on some plans. In these cases, BCBS AL may require a documented 90-day trial of metformin (or a clinical contraindication such as eGFR <30 mL/min/1.73 m² or a history of lactic acidosis) before approving Farxiga. Some plans also require a trial of a sulfonylurea or a DPP-4 inhibitor as a second step before authorizing an SGLT2 inhibitor.

What You Can Expect to Pay Out of Pocket

Your actual cost for Farxiga through BCBS AL depends on four variables: your plan's tier placement, whether your deductible has been met, your pharmacy network status, and whether you qualify for manufacturer or third-party assistance.

Without insurance, Farxiga's wholesale acquisition cost (WAC) runs approximately $580 to $620 for a 30-day supply of 10 mg tablets. Few patients pay this amount. With BCBS AL commercial coverage and Tier 2 placement, expect a copay between $35 and $60 per month after any applicable deductible. Tier 3 placement with coinsurance could mean $90 to $150 per fill, especially early in the plan year before the deductible is satisfied.

AstraZeneca offers a manufacturer savings card that can reduce out-of-pocket costs to as low as $0 per month for eligible commercially insured patients, with a maximum annual benefit of $1,800. This card cannot be used with Medicare, Medicaid, or other federal healthcare programs 3. Patients on BCBS AL Medicare Advantage plans may instead benefit from the $2,000 Part D out-of-pocket cap or AstraZeneca's patient assistance program (AZ&Me), which provides free medication to qualifying uninsured or underinsured individuals.

Mail-order pharmacy through BCBS AL's preferred partner can sometimes reduce per-fill costs by 10% to 20% compared to retail pharmacies. A 90-day mail-order supply often costs the equivalent of two retail copays rather than three.

Clinical Evidence Supporting Farxiga Coverage

Insurers like BCBS AL base formulary decisions partly on the strength of clinical trial evidence. Farxiga has one of the broadest evidence bases among SGLT2 inhibitors, spanning diabetes, heart failure, and kidney disease.

The DECLARE-TIMI 58 trial (N=17,160) evaluated dapagliflozin 10 mg versus placebo in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors. Over a median follow-up of 4.2 years, dapagliflozin significantly reduced the composite of cardiovascular death or hospitalization for heart failure (HR 0.83 to 95% CI 0.73 to 0.95, P=0.005) 4. The drug did not reduce major adverse cardiovascular events (MACE) in the overall population, but the heart failure benefit was consistent across subgroups.

In the DAPA-CKD trial (N=4,304), dapagliflozin reduced the composite of sustained eGFR decline of 50% or more, end-stage kidney disease, or renal or cardiovascular death by 39% compared to placebo (HR 0.61 to 95% CI 0.51 to 0.72, P<0.001) 5. This benefit held regardless of diabetes status, which led the FDA to expand Farxiga's indication to chronic kidney disease in April 2021.

The DAPA-HF trial (N=4,744) showed that dapagliflozin reduced the composite of worsening heart failure or cardiovascular death by 26% in patients with heart failure and reduced ejection fraction (HR 0.74 to 95% CI 0.65 to 0.85, P<0.001), again irrespective of diabetes status 6.

Dr. John McMurray, lead investigator of DAPA-HF and professor of cardiology at the University of Glasgow, stated: "Dapagliflozin reduced the risk of worsening heart failure and death from cardiovascular causes by a clinically meaningful margin in patients both with and without diabetes."

The ADA Standards of Care (2024) recommend SGLT2 inhibitors as preferred add-on therapy for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, independent of A1C level or metformin use 2. This guideline position strengthens the clinical case when submitting prior authorization requests to BCBS AL.

How to Appeal a Coverage Denial

If BCBS AL denies coverage for Farxiga, you have the right to file an appeal. The process involves multiple levels, and success rates improve substantially when appeals include targeted clinical documentation.

Start with a Level 1 internal appeal within 180 days of the denial. Your physician should submit a letter of medical necessity that addresses the specific denial reason. If BCBS AL denied based on step therapy, the letter should document prior medication trials, dates, doses, and reasons for discontinuation (adverse effects, inadequate glycemic control, contraindications). Include lab values: A1C, fasting glucose, eGFR, UACR, and BNP or NT-proBNP if heart failure is part of the clinical picture.

A peer-to-peer review request can sometimes resolve denials faster than a written appeal. Your prescriber calls BCBS AL's medical director to discuss the case directly. This is especially effective when the patient has a comorbidity (heart failure, CKD) that makes Farxiga the guideline-recommended agent rather than simply one option among several.

If the internal appeal fails, you can request an external review through the Alabama Department of Insurance. An independent review organization (IRO) evaluates the case using current medical literature and clinical guidelines. According to the Kaiser Family Foundation, external reviews overturn insurer denials in approximately 40% to 50% of cases for prescription drug appeals 7.

The Endocrine Society's clinical practice guidelines for type 2 diabetes management recommend SGLT2 inhibitors in patients with eGFR above 20 mL/min/1.73 m² and either albuminuria, heart failure, or established cardiovascular disease 8. Citing these guidelines in an appeal strengthens the argument that Farxiga is medically necessary rather than a physician preference.

Farxiga vs. Other SGLT2 Inhibitors on BCBS AL Formularies

BCBS AL covers multiple SGLT2 inhibitors, and the relative tier placement can shift your out-of-pocket cost significantly. Understanding where Farxiga sits compared to its competitors helps you and your physician make an informed choice.

Jardiance (empagliflozin) is the most common formulary competitor. On many BCBS AL plans, Jardiance and Farxiga occupy the same tier. However, certain plan designs place one as preferred and the other as non-preferred based on negotiated rebate agreements between BCBS AL and the manufacturers (AstraZeneca for Farxiga, Boehringer Ingelheim/Lilly for Jardiance). If your plan prefers Jardiance over Farxiga, switching may reduce your copay without sacrificing clinical benefit, as both drugs have demonstrated cardiovascular and renal protective effects in large outcome trials.

Invokana (canagliflozin) is a third SGLT2 option but often sits on a higher tier due to its association with increased amputation risk identified in the CANVAS trial 9. The ADA notes that this risk signal, while not confirmed in post-marketing studies at the same magnitude, led many formulary committees to deprioritize canagliflozin relative to empagliflozin and dapagliflozin.

Brenzavvy (bexagliflozin), approved in 2023, has limited formulary presence and is not widely covered by BCBS AL plans as of mid-2026.

If BCBS AL requires a specific SGLT2 inhibitor through its formulary and your physician believes Farxiga is clinically preferable (for example, due to the DAPA-CKD data in non-diabetic CKD), a formulary exception request can be filed alongside the prior authorization.

Using AstraZeneca's Patient Support Programs

AstraZeneca operates several programs that can lower or eliminate out-of-pocket costs for Farxiga, and these programs work alongside BCBS AL coverage.

The Farxiga Savings Card is available to commercially insured patients, including those with BCBS AL commercial plans. Eligible patients can pay as little as $0 per 30-day prescription, up to a maximum annual benefit. The card is activated online or through the prescribing physician's office and is applied at the pharmacy point of sale.

The AZ&Me Prescription Savings Program serves uninsured patients or those whose insurance (including Medicare Part D) leaves them with unaffordable costs. Qualifying patients receive Farxiga at no cost. Eligibility is based on household income (typically at or below 400% of the federal poverty level) and lack of adequate prescription coverage.

AstraZeneca also maintains a bridge supply program for patients awaiting prior authorization decisions. If your BCBS AL PA is pending, you may receive up to a 30-day supply of Farxiga at no cost to avoid treatment interruption.

Contact AstraZeneca's patient support line at 1-800-236-9933 or visit the manufacturer's website for current eligibility criteria and enrollment forms.

Special Considerations for Alabama Medicaid and State Employee Plans

Alabama Medicaid covers Farxiga under its preferred drug list, though prior authorization is mandatory and criteria are strict. Medicaid recipients must demonstrate failure of or contraindication to at least one first-line oral agent (typically metformin) and have documented A1C above 7.0% despite adherence to current therapy.

The State Employees' Health Insurance Plan (SEHIP) in Alabama, administered by BCBS AL, follows its own formulary that often mirrors but does not duplicate the commercial BCBS AL drug list. SEHIP members should verify Farxiga's tier status through the SEHIP-specific formulary rather than assuming it matches standard BCBS AL commercial plans.

For dual-eligible patients (those with both Medicare and Medicaid), Medicaid serves as the secondary payer and may cover remaining copays or coinsurance after Medicare Part D processes the claim. The $2,000 annual Part D out-of-pocket cap applies first, and Medicaid picks up residual cost-sharing in most cases.

Monitoring and Follow-Up After Starting Farxiga

Once BCBS AL approves Farxiga, your prescriber should establish a monitoring schedule consistent with ADA recommendations. Baseline labs before starting Farxiga include serum creatinine with eGFR, serum potassium, A1C, lipid panel, and urinalysis. Repeat eGFR at 1 month and then every 3 to 6 months is standard practice 2.

An initial eGFR dip of 10% to 15% is expected within the first 2 to 4 weeks and should not prompt discontinuation. The DAPA-CKD trial confirmed that this early hemodynamic dip is reversible and does not predict long-term kidney function decline 5.

Watch for signs of euglycemic diabetic ketoacidosis (DKA), a rare but serious SGLT2 inhibitor adverse effect occurring at a rate of approximately 0.1% to 0.2% per year. The FDA issued a safety communication in 2015 and updated it in 2020, warning that patients should stop Farxiga and seek emergency care if they develop nausea, vomiting, abdominal pain, or malaise with blood glucose below 250 mg/dL and confirmed ketonemia 10.

BCBS AL typically approves Farxiga for a 12-month authorization period. Reauthorization requires updated clinical documentation, including current A1C, eGFR, and a note confirming continued medical necessity. Submit reauthorization paperwork 30 days before expiration to prevent gaps in coverage.